insights_auto
LONA の上昇理由: 22.30%?
さらに詳しくchevron_right
LONA:NASDAQ
LeonaBio Inc
$3.51
arrow_upward
+22.30%(+0.64) 1 日
$3.50
arrow_downward
-0.28% (-0.0100)bedtime時間外取引
終了: 9月29日, 16:00:01 GMT-4 · USD
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_autoLONA の上位の分析情報を生成しています...
始値
$2.80
高値
$3.75
安値
$2.57
時価総額
3307.00万
平均出来高
10.76万
取引量
43.91万
52 週高値
$14.19
52 週安値
$2.21
EPS
-$19.72
ベータ版
2.05
発行済株式数
942.20万
従業員数
19
始値
$2.80
高値
$3.75
安値
$2.57
時価総額
3307.00万
平均出来高
10.76万
取引量
43.91万
52 週高値
$14.19
52 週安値
$2.21
EPS
-$19.72
ベータ版
2.05
発行済株式数
942.20万
従業員数
19
ニュース記事
情報源: ウェブソース、ニュース パートナー
プロフィール
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
LeonaBio Inc について